Shattuck Labs, Inc. (NASDAQ:STTK) saw unusually-high trading volume on Thursday . Approximately 9,220 shares were traded during trading, a decline of 92% from the previous session’s volume of 121,803 shares.The stock last traded at $28.43 and had previously closed at $27.21.
Several research firms have recently weighed in on STTK. Zacks Investment Research downgraded Shattuck Labs from a “hold” rating to a “sell” rating in a research report on Saturday, March 20th. Evercore ISI began coverage on Shattuck Labs in a research report on Monday, January 11th. They set an “outperform” rating for the company. Finally, Citigroup lifted their target price on Shattuck Labs from $36.00 to $75.00 in a research report on Wednesday, January 20th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $45.25.
The company’s fifty day moving average price is $36.63.
Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Sunday, March 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. The company had revenue of $1.34 million during the quarter. As a group, equities analysts predict that Shattuck Labs, Inc. will post -1.82 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Pacer Advisors Inc. purchased a new position in Shattuck Labs in the first quarter valued at about $25,000. Citigroup Inc. purchased a new position in Shattuck Labs in the fourth quarter valued at about $130,000. Strs Ohio purchased a new stake in shares of Shattuck Labs during the fourth quarter worth about $167,000. Alliancebernstein L.P. purchased a new stake in shares of Shattuck Labs during the fourth quarter worth about $204,000. Finally, Credit Suisse AG purchased a new stake in shares of Shattuck Labs during the fourth quarter worth about $209,000.
About Shattuck Labs (NASDAQ:STTK)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Story: Why Invest in Dividend Achievers?
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.